RESEARCH STUDIES AT ADC MIDWEST
Learn about our RESEARCH STUDIES and find a study that might be right for you.
RESEARCH STUDIES AT ADC MIDWEST
CURRENT STUDIES
ANAL CANCER PREVENTION STUDY (ANCHOR Study)
Active, not recruiting, results reported.
The ANCHOR Study is a National Institutes of Health (NIH)-funded study with the primary objective of determining whether treating anal precancer will reduce the incidence of anal cancer in people living with HIV. The ANCHOR Study is the first randomized study to show that treating anal precancer reduces anal cancer by 57%. The ANCHOR Study is no longer enrolling new participants but will continue to follow its current participants through 2024.
Inovio VGX-3100 and Electroporation in treating HIV-positive Patients with Anal High-Grade Intraepithelial Lesions (HSIL)
Active, recruiting.
This study will give you an immunotherapy treatment called VGX-3100 to your to produce specifically designed antigens to stimulate your immune system to produce a special immune (disease-fighting) response to potentially get rid of anal precancer (HSIL) in HIV- positive patients. All study participants will get the same VGX-3100.
For details about the eligibility criteria please contact Gary Bucher, MD at 312-623-ANAL or email at
[email protected]
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL (anal HSIL HIV-)
Active, recruiting.
This study will evaluate the effectiveness of four 5-day cycles of artesunate suppositories in patients with intra-anal precancer (HSIL).
For details about the eligibility criteria please contact Gary Bucher, MD at 312-623-2625 or email at
[email protected]
PAST RESEARCH STUDIES
Inovio Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri- Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Completed, results reported.
This study evaluated an immunotherapy treatment called VGX-3100 to stimulate the immune system to
produce a special immune (disease-fighting) response to potentially get rid of anal precancer (HSIL) in
HIV-negative patients.
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Inovio Phase 2, Open Label, Study of VGX-3100 Delivered
Intramuscularly (IM) Followed by Electroporation (EP) for the
Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri- Anal,
High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3,
PAIN2, PAIN3) in Individuals That Are Seronegative for Human
Immunodeficiency Virus (HIV)-1/2
Completed.
This study evaluated a topical cream for treating intra-anal precancer.